The first treatment to be recommended by the National Institute for Health and Care Excellence (NICE) for treating acute migraine will soon be available on the NHS to around 13,000 people. NICE has published draft guidance recommending rimegepant as a cost-effective option for the acute treatment of migraine in adults. NICE has previously recommended treatments, including rimegepant, for preventing migraine in adults.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
